Applicability of Bilastine in Children Aged 6 to 11 Years with Allergic Rhinoconjunctivitis or Chronic Urticaria


eMediNexus    16 December 2022

Bilastine is a second-generation antihistamine employed for treating allergic rhinoconjunctivitis and urticaria in adults and children aged ≥6 years. The present study extracted the pharmacokinetic data for children aged 6 to 11 years from a study in which children (2-11 years) with allergic rhinoconjunctivitis or urticaria received bilastine 10 mg/day orally. It compared the maximum plasma concentration (Cmax) and area under the plasma concentration curve (AUC) data with adult pharmacokinetic data from seven clinical studies (bilastine 20 mg/day). It also extracted the safety data for children aged 6 to 11 years from a phase III randomized controlled trial in which children (aged 2-11 years) with allergic rhinoconjunctivitis or chronic urticaria received once-daily bilastine 10 mg or placebo for 12 weeks. 


The study observed:


  • Similar exposure and Cmax values for children (6-11 years) and adults, with median pediatric/adult ratios for AUC0-24 and Cmax as 0.93 and 0.91, respectively.
  • No significant difference in the incidence of treatment-emergent adverse in children (6-11 years) who received bilastine 10 mg or placebo.


This pharmacokinetic and safety analysis, conducted in children aged 6 to 11 years, supports the suitability of the pediatric dose of bilastine 10 mg and confirms the comparable safety profiles between bilastine and placebo.


Source: Rodríguez M, Vozmediano V, García-Bea A, et al. Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria. Eur J Pediatr. 2020;179(5):801-5. 

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.